AEterna Zentaris Stock Price, News & Analysis (NASDAQ:AEZS)

$2.18 -0.02 (-0.91 %)
(As of 12/13/2017 01:49 PM ET)
Previous Close$2.20
Today's Range$2.13 - $2.22
52-Week Range$0.78 - $4.25
Volume226,800 shs
Average Volume1.01 million shs
Market Capitalization$36.17 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87

About AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris logoAeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AEZS
CUSIPN/A
Phone843-900-3211

Debt

Debt-to-Equity RatioN/A
Current Ratio2.32%
Quick Ratio2.32%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$910,000.00
Price / Sales39.38
Cash FlowN/A
Price / CashN/A
Book Value$0.48 per share
Price / Book4.54

Profitability

Trailing EPS($1.81)
Net Income$-24,950,000.00
Net Margins-2,338.61%
Return on Equity-732.74%
Return on Assets-96.77%

Miscellaneous

Employees47
Outstanding Shares16,440,000

AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) issued its earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.82) by $0.11. The biopharmaceutical company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.50 million. AEterna Zentaris had a negative return on equity of 732.74% and a negative net margin of 2,338.61%. View AEterna Zentaris' Earnings History.

When will AEterna Zentaris make its next earnings announcement?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for AEterna Zentaris.

Where is AEterna Zentaris' stock going? Where will AEterna Zentaris' stock price be in 2017?

3 Wall Street analysts have issued 12-month price targets for AEterna Zentaris' shares. Their forecasts range from $3.00 to $6.00. On average, they anticipate AEterna Zentaris' share price to reach $4.33 in the next twelve months. View Analyst Ratings for AEterna Zentaris.

What are Wall Street analysts saying about AEterna Zentaris stock?

Here are some recent quotes from research analysts about AEterna Zentaris stock:

  • 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (7/11/2017)
  • 2. Maxim Group analysts commented, "Summary Aeterna Zentaris announced its plan to file a new drug application (NDA) for Macrilen (macimorelin) for adults growth hormone deficiency (AGHD) in 3Q17, following its meeting with the FDA on March 29, 2017." (3/30/2017)

Who are some of AEterna Zentaris' key competitors?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:

  • Carolyn Egbert, Independent Chairman of the Board
  • Michael Ward, President, Chief Executive Officer, Director
  • Jeffrey A. Whitnell CPA, Interim Chief Financial Officer (Age 58)
  • Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
  • Jude Dinges, Chief Commercial Officer, Senior Vice President
  • Eckhard G. Gunther Ph.D., Vice President - Alliance Management
  • Michael Teifel, Vice President - Non-Clinical Sciences
  • John W. Sharkey Ph.D., Business Development Consultant (Age 60)
  • Philip Allen Theodore, Corporate Secretary (Age 64)
  • David A. Dodd, Director (Age 65)

Who owns AEterna Zentaris stock?

AEterna Zentaris' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (0.35%). View Institutional Ownership Trends for AEterna Zentaris.

Who bought AEterna Zentaris stock? Who is buying AEterna Zentaris stock?

AEterna Zentaris' stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. View Insider Buying and Selling for AEterna Zentaris.

How do I buy AEterna Zentaris stock?

Shares of AEterna Zentaris can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEterna Zentaris stock can currently be purchased for approximately $2.18.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of $36.17 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-24,950,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis. AEterna Zentaris employs 47 workers across the globe.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 1 PLACE VILLE MARIE SUITE 2500, MONTREAL A8, H3B 1R1. The biopharmaceutical company can be reached via phone at 843-900-3211 or via email at [email protected]


MarketBeat Community Rating for AEterna Zentaris (AEZS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AEterna Zentaris (NASDAQ:AEZS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.33$4.33$4.33$3.67
Price Target Upside: 106.35% upside150.48% upside150.48% upside336.92% upside

AEterna Zentaris (NASDAQ:AEZS) Consensus Price Target History

Price Target History for AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris (NASDAQ:AEZS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2017HC WainwrightSet Price TargetBuy$3.00MediumView Rating Details
11/28/2017Maxim GroupSet Price TargetBuy$4.00LowView Rating Details
1/8/2017Canaccord GenuitySet Price TargetBuy$7.50 -> $6.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

AEterna Zentaris (NASDAQ:AEZS) Earnings History and Estimates Chart

Earnings by Quarter for AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris (NASDAQ AEZS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
8/10/20176/30/2017($0.41)($0.46)$0.22 million$0.24 millionViewN/AView Earnings Details
5/8/20173/31/2017($0.33)($0.31)$0.85 million$0.26 millionViewListenView Earnings Details
3/15/201712/31/2016($0.73)($0.71)$0.40 million$0.30 millionViewN/AView Earnings Details
11/8/2016Q316($0.74)($0.61)$0.22 million$0.27 millionViewListenView Earnings Details
5/9/2016Q216($0.82)($0.71)$0.50 million$0.24 millionViewN/AView Earnings Details
3/29/2016Q415($1.30)($1.46)$0.25 million$0.10 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.07)$0.20 million$0.17 millionViewN/AView Earnings Details
8/13/2015Q215($0.08)($0.14)$0.55 million$0.20 millionViewListenView Earnings Details
5/7/2015Q1 2015($0.10)($0.13)$0.07 millionViewN/AView Earnings Details
3/17/2015Q414($0.16)$0.06$0.01 millionViewN/AView Earnings Details
3/20/2014Q413($0.04)($0.22)$12.41 millionViewN/AView Earnings Details
3/21/2013Q412($0.31)($0.29)$7.96 million$9.16 millionViewN/AView Earnings Details
11/13/2012Q312($0.43)($0.35)$8.38 million$7.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

AEterna Zentaris (NASDAQ:AEZS) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.5 EPS
Next Year EPS Consensus Estimate: $-0.77 EPS

Dividends

Dividend History for AEterna Zentaris (NASDAQ:AEZS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AEterna Zentaris (NASDAQ AEZS)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

AEterna Zentaris (NASDAQ AEZS) News Headlines

Source:
DateHeadline
Aeterna Zentaris (AEZS) Interim Chief Financial Officer Departs - StreetInsider.comAeterna Zentaris (AEZS) Interim Chief Financial Officer Departs - StreetInsider.com
www.streetinsider.com - December 8 at 3:18 PM
Ahead of Big Catalyst, AEterna Zentaris Inc. (AEZS) Announced Departure of Interim Chief Financial OfficerAhead of Big Catalyst, AEterna Zentaris Inc. (AEZS) Announced Departure of Interim Chief Financial Officer
finance.yahoo.com - December 8 at 3:18 PM
Biotechs Flying Under The Radar - PR Newswire (press release)Biotech's Flying Under The Radar - PR Newswire (press release)
www.prnewswire.com - December 6 at 3:19 PM
HC Wainwright Analysts Give AEterna Zentaris (AEZS) a $3.00 Price TargetHC Wainwright Analysts Give AEterna Zentaris (AEZS) a $3.00 Price Target
www.americanbankingnews.com - November 29 at 7:30 PM
AEterna Zentaris (AEZS) Given a $4.00 Price Target by Maxim Group AnalystsAEterna Zentaris (AEZS) Given a $4.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - November 28 at 3:36 PM
Aeterna Zentaris (AEZS) Says MAA for Macrilen for Evaluation of Adult Growth Hormone Deficiency Accepted by EMAAeterna Zentaris (AEZS) Says MAA for Macrilen for Evaluation of Adult Growth Hormone Deficiency Accepted by EMA
www.streetinsider.com - November 28 at 3:18 PM
(AEZS) (TECD) Higher; (ASC) (CPRX) - StreetInsider.com - StreetInsider.com(AEZS) (TECD) Higher; (ASC) (CPRX) - StreetInsider.com - StreetInsider.com
www.streetinsider.com - November 28 at 7:37 AM
Aeterna Zentaris (AEZS) Says MAA for Macrilen for Evaluation of ... - StreetInsider.comAeterna Zentaris (AEZS) Says MAA for Macrilen for Evaluation of ... - StreetInsider.com
www.streetinsider.com - November 28 at 7:37 AM
BIIB & ALKS Team Up For MS Drug, REGNs Eylea Combo Fails Again, AEZS Rises - NasdaqBIIB & ALKS Team Up For MS Drug, REGN's Eylea Combo Fails Again, AEZS Rises - Nasdaq
www.nasdaq.com - November 28 at 7:37 AM
AEterna Zentaris Inc.’s (USA) (AEZS) Growth Hormone Drug Accepted for EU ReviewAEterna Zentaris Inc.’s (USA) (AEZS) Growth Hormone Drug Accepted for EU Review
finance.yahoo.com - November 28 at 7:37 AM
Aeterna Zentaris’ Marketing Authorization Application for Macrilen™ (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines AgencyAeterna Zentaris’ Marketing Authorization Application for Macrilen™ (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency
finance.yahoo.com - November 28 at 7:37 AM
AEterna Zentaris Inc. (AEZS) Expected to Post Earnings of -$0.42 Per ShareAEterna Zentaris Inc. (AEZS) Expected to Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - November 15 at 9:47 AM
 Brokerages Set $3.50 Target Price for AEterna Zentaris Inc. (AEZS) Brokerages Set $3.50 Target Price for AEterna Zentaris Inc. (AEZS)
www.americanbankingnews.com - November 14 at 1:50 AM
Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 13 at 6:17 PM
Aeterna Zentaris (AEZS) CEO Michael Ward on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAeterna Zentaris' (AEZS) CEO Michael Ward on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 11 at 3:23 PM
Aeterna Zentaris reports 3Q lossAeterna Zentaris reports 3Q loss
finance.yahoo.com - November 9 at 4:31 PM
AEterna Zentaris Inc. (AEZS) Posts  Earnings Results, Misses Estimates By $0.20 EPSAEterna Zentaris Inc. (AEZS) Posts Earnings Results, Misses Estimates By $0.20 EPS
www.americanbankingnews.com - November 9 at 2:27 PM
Company Update: AEterna Zentaris Inc. (AEZS) Announces 3Q:17 Highlights and Financial ResultsCompany Update: AEterna Zentaris Inc. (AEZS) Announces 3Q:17 Highlights and Financial Results
finance.yahoo.com - November 8 at 10:36 PM
Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating ResultsAeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results
finance.yahoo.com - November 8 at 5:31 PM
AEterna Zentaris Inc. (AEZS) Set to Announce Quarterly Earnings on WednesdayAEterna Zentaris Inc. (AEZS) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 3 at 10:59 AM
Aeterna Zentaris to Announce Third Quarter 2017 Financial and Operating Results on November 8, 2017Aeterna Zentaris to Announce Third Quarter 2017 Financial and Operating Results on November 8, 2017
finance.yahoo.com - November 2 at 8:42 PM
Infinity Pharmaceuticals (INFI) vs. AEterna Zentaris (AEZS) Financial ReviewInfinity Pharmaceuticals (INFI) vs. AEterna Zentaris (AEZS) Financial Review
www.americanbankingnews.com - October 27 at 3:30 AM
Investor urges Power Corp to sell C$10 billion in assets - ReutersInvestor urges Power Corp to sell C$10 billion in assets - Reuters
www.reuters.com - October 24 at 3:55 PM
Aeterna Zentaris Announces Appointment of Interim Chief Financial OfficerAeterna Zentaris Announces Appointment of Interim Chief Financial Officer
www.businesswire.com - September 27 at 8:18 PM
Head-To-Head Comparison: AEterna Zentaris (AEZS) vs. Its PeersHead-To-Head Comparison: AEterna Zentaris (AEZS) vs. Its Peers
www.americanbankingnews.com - September 19 at 8:10 PM
Aeterna Zentaris (AEZS) VP, Finance & Chief Accounting Officer Departs - StreetInsider.comAeterna Zentaris (AEZS) VP, Finance & Chief Accounting Officer Departs - StreetInsider.com
www.streetinsider.com - September 3 at 1:31 AM
Aeterna Zentaris (AEZS) VP, Finance & Chief Accounting Officer DepartsAeterna Zentaris (AEZS) VP, Finance & Chief Accounting Officer Departs
www.streetinsider.com - September 2 at 2:14 AM
Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting OfficerAeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer
finance.yahoo.com - September 1 at 9:12 PM
Short Interest in AEterna Zentaris Inc. (AEZS) Drops By 29.7%Short Interest in AEterna Zentaris Inc. (AEZS) Drops By 29.7%
www.americanbankingnews.com - August 29 at 1:06 AM
Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 3:33 PM
Todays Research Reports on Stocks to Watch: EnteroMedics and Aterna ZentarisToday's Research Reports on Stocks to Watch: EnteroMedics and Aterna Zentaris
finance.yahoo.com - August 14 at 3:56 PM
AEterna Zentaris Inc. (NASDAQ:AEZS) Short Interest UpdateAEterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update
www.americanbankingnews.com - August 13 at 1:46 AM
Investor Network: Aeterna Zentaris Inc. to Host Earnings CallInvestor Network: Aeterna Zentaris Inc. to Host Earnings Call
finance.yahoo.com - August 11 at 4:01 PM
Maxim Group Analysts Give AEterna Zentaris Inc. (AEZS) a $4.00 Price TargetMaxim Group Analysts Give AEterna Zentaris Inc. (AEZS) a $4.00 Price Target
www.americanbankingnews.com - August 11 at 1:26 PM
Aeterna Zentaris Q2 beat propels shares, up 15% premarketAeterna Zentaris Q2 beat propels shares, up 15% premarket
seekingalpha.com - August 11 at 8:55 AM
AEterna Zentaris Inc. (NASDAQ:AEZS) Releases  Earnings Results, Beats Estimates By $0.20 EPSAEterna Zentaris Inc. (NASDAQ:AEZS) Releases Earnings Results, Beats Estimates By $0.20 EPS
www.americanbankingnews.com - August 10 at 11:02 PM
Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results - Business Wire (press release)Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results - Business Wire (press release)
www.businesswire.com - August 10 at 10:00 PM
Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating ResultsAeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results
finance.yahoo.com - August 10 at 10:00 PM
Aeterna Zentaris reports 2Q lossAeterna Zentaris reports 2Q loss
finance.yahoo.com - August 10 at 10:00 PM
Aeterna Zentaris (AEZS) Hires Financial Advisor to Review AlternativesAeterna Zentaris (AEZS) Hires Financial Advisor to Review Alternatives
www.streetinsider.com - August 9 at 3:47 PM
Aeterna Zentaris (AEZS) Hires Financial Advisor to Review Alternatives - StreetInsider.comAeterna Zentaris (AEZS) Hires Financial Advisor to Review Alternatives - StreetInsider.com
www.streetinsider.com - August 9 at 1:44 AM
Aeterna Zentaris Engages Advisors and Provides Update to ShareholdersAeterna Zentaris Engages Advisors and Provides Update to Shareholders
finance.yahoo.com - August 8 at 8:40 PM
AEterna Zentaris Inc. (NASDAQ:AEZS) to Release Earnings on ThursdayAEterna Zentaris Inc. (NASDAQ:AEZS) to Release Earnings on Thursday
www.americanbankingnews.com - August 7 at 10:48 AM
Aeterna Zentaris to Announce Second Quarter 2017 Financial and Operating Results on August 10, 2017 - Business Wire (press release)Aeterna Zentaris to Announce Second Quarter 2017 Financial and Operating Results on August 10, 2017 - Business Wire (press release)
www.businesswire.com - August 4 at 8:47 PM
Aeterna Zentaris to Announce Second Quarter 2017 Financial and Operating Results on August 10, 2017Aeterna Zentaris to Announce Second Quarter 2017 Financial and Operating Results on August 10, 2017
finance.yahoo.com - August 4 at 8:47 PM
Aeterna Zentaris goes after former execs over alleged scheme to control company; shares up 14%Aeterna Zentaris goes after former execs over alleged scheme to control company; shares up 14%
seekingalpha.com - August 4 at 11:39 AM
Aeterna Zentaris Commences Legal Action Against David Dodd and Philip Theodore - Business Wire (press release)Aeterna Zentaris Commences Legal Action Against David Dodd and Philip Theodore - Business Wire (press release)
www.businesswire.com - August 3 at 4:07 PM
Aeterna Zentaris Commences Legal Action Against David Dodd and Philip TheodoreAeterna Zentaris Commences Legal Action Against David Dodd and Philip Theodore
finance.yahoo.com - August 3 at 4:07 PM
Wall Streets M&A Chatter From July 25: Aeterna Zentaris, Rent-A-Center, Michael Kors-Jimmy Choo - BenzingaWall Street's M&A Chatter From July 25: Aeterna Zentaris, Rent-A-Center, Michael Kors-Jimmy Choo - Benzinga
www.benzinga.com - July 26 at 3:33 PM
Will FDA Catalyst Put Aeterna Zentaris Shares Back on Track?Will FDA Catalyst Put Aeterna Zentaris Shares Back on Track?
finance.yahoo.com - July 25 at 3:23 PM

SEC Filings

AEterna Zentaris (NASDAQ:AEZS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AEterna Zentaris (NASDAQ:AEZS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AEterna Zentaris (NASDAQ AEZS) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.